Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.
Saved in:
| Title: | Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial. |
|---|---|
| Authors: | Wander SA; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: swander@mgh.harvard.edu., Lloyd MR; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Keenan JC; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Scott EC; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Niemierko A; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Spring LM; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fell GG; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Shin J; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Isakoff SJ; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Moy B; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ryan L; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Padden S; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Fisher E; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Newton A; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Habin KR; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Viscosi-Spieler ET; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Scarpetti L; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Varkaris A; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Ellisen LW; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Dubash T; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Che D; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Patel PS; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., de la Cruz FF; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Sutaria DS; Genentech, South San Francisco, CA, USA., Sane RS; Genentech, South San Francisco, CA, USA., Micalizzi DS; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Maheswaran S; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Haber DA; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Juric D; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Bardia A; Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2026 May; Vol. 27 (5), pp. 580-591. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
